CoChat

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

Open access
Hsieh, Rodney Cheng-En, Krishnan, Sunil, Wu, Ren-Chin, Boda, Akash R., Liu, Arthur, Winkler, Michelle, Hsu, Wen-Hao, Lin, Steven Hsesheng, Hung, Mien-Chie, Chan, Li-Chuan, Bhanu, Krithikaa Rajkumar, Srinivasamani, Anupallavi, De Azevedo, Ricardo Alexandre, Chou, Yung-Chih, DePinho, Ronald A., Gubin, Matthew, Vilar, Eduardo, Chen, Chao Hsien, Slay, Ravaen, Jayaprakash, Priyamvada, Hegde, Shweta Mahendra, Hartley, Genevieve, Lea, Spencer T., Prasad, Rishika, Morrow, Brittany, Couillault, Coline Agnes, Steiner, Madeline, Wang, Chun-Chieh, Venkatesulu, Bhanu Prasad, Taniguchi, Cullen, Kim, Yon Son Betty, Chen, Junjie, Rudqvist, Nils-Petter, Curran, Michael A. · 2022 · Science Immunology
Cited by 182

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor remissions are extremely rare, and the postirradiation immune escape mechanisms in CRC remain elusive. Here, we found that irradiated CRC cells used ATR-mediated DNA repair signaling pathway to up-regulate both CD47 and PD-L1, which through engagement of SIRPα and PD-1, respectively, prevented phagocytosis by antigen-presenting cells and thereby limited TAA cross-presentation and innate immune activation. This postirradiation CD47 and PD-L1 up-regulation was observed across various human solid tumor cells. Concordantly, rectal cancer patients with poor responses to neoadjuvant RT exhibited significantly elevated postirradiation CD47 levels. The combination of RT, anti-SIRPα, and anti–PD-1 reversed adaptive immune resistance and drove efficient TAA cross-presentation, resulting in robust TAA-specific CD8 T cell priming, functional activation of T effectors, and increased T cell clonality and clonal diversity. We observed significantly higher complete response rates to RT/anti-SIRPα/anti–PD-1 in both irradiated and abscopal tumors and prolonged survival in three distinct murine CRC models, including a cecal orthotopic model. The efficacy of triple combination therapy was STING dependent as knockout animals lost most benefit of adding anti-SIRPα and anti–PD-1 to RT. Despite activation across the myeloid stroma, the enhanced dendritic cell function accounts for most improvements in CD8 T cell priming. These data suggest ATR-mediated CD47 and PD-L1 up-regulation as a key mechanism restraining radiation-induced immune priming. RT combined with SIRPα and PD-1 blockade promotes robust antitumor immune priming, leading to systemic tumor regressions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciimmunol.abl9330

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

Metadata

Authors
Hsieh, R. C.-E., Krishnan, S., Wu, R.-C., Boda, A. R., Liu, A., Winkler, M., Hsu, W.-H., Lin, S. H., Hung, M.-C., Chan, L.-C., Bhanu, K. R., Srinivasamani, A., De Azevedo, R. A., Chou, Y.-C., DePinho, R. A., Gubin, M., Vilar, E., Chen, C. H., Slay, R., Jayaprakash, P., Hegde, S. M., Hartley, G., Lea, S. T., Prasad, R., Morrow, B., Couillault, C. A., Steiner, M., Wang, C.-C., Venkatesulu, B. P., Taniguchi, C., Kim, Y. S. B., Chen, J., Rudqvist, N.-P., & Curran, M. A.
Venue
Science Immunology
Published
2022-06-24
Volume
7
Issue
72
Pages
eabl9330-eabl9330
ISSN
2470-9468 (ISSN-L)
OpenAlex
W4281724792
Cited by
182
References
11
FWCI
11.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.